During the last session, CTI BioPharma Corp. (NASDAQ:CTIC)’s traded shares were 1,874,928, with the beta value of the company hitting 0.81. At the end of the trading day, the stock’s price was $2.56, reflecting an intraday loss of -2.29% or -$0.06. The 52-week high for the CTIC share is $4.13, that puts it down -61.33% from that peak though still a striking +66.41% gain since the share price plummeted to a 52-week low of $0.86. The company’s market capitalization is $232.83 Million, and the average intraday trading volume over the past 10 days was 3.15 Million shares, and the average trade volume was 822.95 Million shares over the past three months.
CTI BioPharma Corp. (CTIC) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2. CTIC has a Sell rating from none of the analyst(s) out of 4 analysts who have looked at this stock. Neither of the analyst(s) recommend to Hold the stock while none of them suggest Overweight, and 4 recommend a Buy rating for it. None of the analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.23.
CTI BioPharma Corp. (NASDAQ:CTIC): Trading Information
CTI BioPharma Corp. (CTIC) registered a -2.29% downside in the last session and has traded in the red over the past 5 sessions. The stock spiked 16.88% in intraday trading to $3.08- this Wednesday, Mar 31, hitting a weekly high. The stock’s 5-day price performance is -4.48%, and it has moved by -13.8% in 30 days. Despite these dips, the overall price performance for the year is -20.5%. The short interest in CTI BioPharma Corp. (NASDAQ:CTIC) is 401.32 Million shares and it means that shorts have 0.49 day(s) to cover.
The consensus price target of analysts on Wall Street is $7.7, which implies an increase of 200.78% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4 and $13 respectively. As a result, CTIC is trading at a discount of 407.81% off the target high and 56.25% off the low.
CTI BioPharma Corp. (CTIC) projections and forecasts
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 35.3%. While earnings are projected to return -6.8% in 2021, the next five years will return 0% per annum.
CTI BioPharma Corp. (NASDAQ:CTIC)’s Biggest Investors
CTI BioPharma Corp. insiders own 0.21% of total outstanding shares while institutional holders control 50.69%, with the float percentage being 50.8%. Orbimed Advisors LLC. is the largest shareholder of the company, while 77 institutions own stock in it. As of Dec 30, 2020, the company held over 9.52 Million shares (or 12.41% of all shares), a total value of $30.66 Million in shares.
The next largest institutional holding, with 7.14 Million shares, is of NEA Management Company, LLC’s that is approximately 9.31% of outstanding shares. At the market price on Dec 30, 2020, these shares were valued at $22.99 Million.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Also, the Mutual Funds coming in first place with the largest holdings of CTI BioPharma Corp. (CTIC) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Dec 30, 2020 indicates that Vanguard Total Stock Market Index Fund owns about 2,095,658 shares. This amounts to just over 2.73 percent of the company’s overall shares, with a $6.75 Million market value. The same data shows that the other fund manager holds slightly less at 723.03 Thousand, or about 0.94% of the stock, which is worth about $2.33 Million.